Epoprostenol

In the US, Epoprostenol (epoprostenol systemic) is a member of the drug class agents for pulmonary hypertension and is used to treat Pulmonary Arterial Hypertension.

US matches:

• Epoprostenol


• Epoprostenol Intravenous


• Epoprostenol Sodium

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

B01AC09

CAS registry number (Chemical Abstracts Service)

0035121-78-9

Chemical Formula

C20-H32-O5

Molecular Weight

352

Therapeutic Categories

Vasodilator

Antiplatelet agent, prostacyclin

Chemical Name

Prosta-5,13-dien-1-oic acid, 6,9-epoxy-11,15-dihydroxy-, (5Z,9α,11α,13E,15S)-

Foreign Names

• Epoprostenolum (Latin)
• Epoprostenol (German)
• Époprosténol (French)
• Epoprostenol (Spanish)

Generic Names

• Epoprostenol (OS: USAN)
• Époprosténol (OS: DCF)
• PGI₂ (IS)
• PGX (IS)
• Prostacyclin (IS)
• Prostaglandin I₂ (IS)
• Prostaglandin X (IS)
• U 53217 (IS)
• Epoprostenol Sodium (OS: BAN, USAN)
• U 53217 A (IS: Upjohn)

Brand Names

• Epoprostenol Sodium
  Actelion, United States; Teva USA, United States



• Flolan
  Glaxo SmithKline, Spain; GlaxoSmithKline, Australia; GlaxoSmithKline, Belgium; GlaxoSmithKline, Canada; GlaxoSmithKline, Switzerland; GlaxoSmithKline, Czech Republic; GlaxoSmithKline, Denmark; GlaxoSmithKline, Estonia; GlaxoSmithKline, France; GlaxoSmithKline, United Kingdom; GlaxoSmithKline, Ireland; GlaxoSmithKline, Israel; GlaxoSmithKline, Italy; GlaxoSmithKline, Japan; GlaxoSmithKline, Luxembourg; GlaxoSmithKline, Malta; GlaxoSmithKline, Netherlands; GlaxoSmithKline, Norway; GlaxoSmithKline, Singapore; GlaxoSmithKline, United States; IFET, Greece

International Drug Name Search

Glossary

BAN	British Approved Name
DCF	Dénomination Commune Française
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.